高级别胶质瘤中的循环生物标志物:当前见解与未来展望
本文综述高级别胶质瘤(HGG)循环生物标志物的研究进展,涵盖循环肿瘤细胞(CTC)、循环肿瘤来源外泌体/细胞外囊泡(ctEV)、循环肿瘤来源DNA(ctDNA)、循环肿瘤来源miRNA(ctmiRNA)及循环肿瘤来源蛋白。这些液体活检标志物在诊断、预后判断、治疗反应监测及靶向治疗开发方面具有潜力,但分别受限于数量少、来源非特异、浓度低及稀释与特异性不足等问题。
要点
- CTC可实时反映肿瘤特征,但循环中数量少使检测困难。
- ctEV携带多种生物分子且易检测,但非肿瘤专属释放,内容异质性需标准化分离分析。
- ctDNA水平与疾病分期相关,但血中浓度低,需高灵敏技术区分正常游离DNA。
核心结论
- 本综述强调循环生物标志物在HGG管理中的变革潜力,对改善患者结局、优化治疗策略及推进神经肿瘤精准肿瘤学实践具有重要意义。
研究设计与样本
- 本文为文献综述,检索并汇总了关于HGG循环生物标志物的文献,包括CTC、ctEV、ctDNA、ctmiRNA及循环肿瘤来源蛋白。
主要发现
- CTC提供肿瘤特征的实时信息,可用于分子分型与治疗反应监测,但循环中数量少使检测具有挑战性。
- ctEV携带多种生物分子且易于检测,但并非仅由肿瘤细胞释放,其内容异质性要求标准化的分离与分析方法。
- ctDNA水平与疾病分期相关,但血中浓度低,需高灵敏技术进行鉴定并与正常游离DNA区分。
- ctmiRNA与肿瘤来源蛋白显示前景,但受易被稀释及当前技术缺乏特异性的限制。
局限性
- CTC在循环中数量少,使检测具有挑战性。
- ctEV并非仅由肿瘤细胞释放,其内容异质性要求标准化的分离与分析方法。
- ctDNA在血中浓度低,需高灵敏技术进行鉴定并与正常游离DNA区分。
- ctmiRNA与肿瘤来源蛋白易被稀释,且当前技术缺乏特异性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: High-grade gliomas (HGG) represent a challenging subset of brain tumors characterized by aggressive nature and poor prognosis. Histopathology remains to be the standard for diagnosis, however, it is invasive, prone to sampling errors, and may not capture the full tumor heterogeneity and evolution over time. In recent years, there has been a growing interest in the potential utility of circulating biomarkers, obtained through minimally-invasive liquid biopsies, providing an opportunity for diagnosis, prognostication, monitoring treatment response and developing targeted therapies. METHODS: We have reviewed the literature on circulating biomarkers for HGG, including circulating tumor cells (CTCs), circulating tumor-derived exosomes/extracellular vesicles (ctEVs), circulating tumor-derived DNA (ctDNA), circulating tumor-derived miRNA (ctmiRNA), and circulating tumor-derived proteins. RESULTS: CTCs provide real-time information about tumor characteristics for molecular profiling and monitoring treatment response, yet their low numbers in circulation makes detection challenging. ctEVs carry a range of biomolecules and are easily detectable. However, they are not exclusively released from tumor cells and heterogeneity in their content requires standardized isolation and analysis methods. ctDNA is another promising biomarker with its levels correlating with the disease stage. However, its low concentration in blood requires highly sensitive techniques for identification and differentiation from normal cell-free DNA. ctmiRNA and tumor-derived proteins show promise but are limited by their susceptibility to dilution and lack of specificity in current technology. CONCLUSION: This review highlights the transformative potential of circulating biomarkers in the management of HGG, with implications for improving patient outcomes, optimizing treatment strategies, and advancing precision oncology in neuro-oncology practice.
引用
- Taori S, Habib A, Adida S, et al. Circulating biomarkers in high-grade gliomas: current insights and future perspectives. J Neurooncol. 2024. PMID: 39671020. doi:10.1007/s11060-024-04903-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。